Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (NQ:QNTM)

7.210 +1.010 (+16.29%)
Streaming Delayed Price Updated: 2:05 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Quantum Biopharma Ltd. - Class B Subordinate Voting Shares

< Previous 1 2 3 4 5 Next >
News headline image
Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern’ Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio
Quarter Shows Company’s Continued Strong Financial Position and Momentum with its MS Clinical Trials and unbuzzd™ Recreational Beverage and Alcohol Metabolizer 
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Announces Private Placement of Class A Multiple Voting Shares
Via Investor Brand Network
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Licensee Unbuzzd Wellness to Host Investor Webinar Oct. 30
Via Investor Brand Network
News headline image
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication
From Quantum BioPharma
Via GlobeNewswire
TinyGemsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Announces Expiration of Final Hedge Fund Warrants and Confirms Oct. 27 CVR Record Date
Via Investor Brand Network
News headline image
Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend
From Quantum BioPharma
Via GlobeNewswire
News headline image
KILL QNTM Investors Have Opportunity to Join Quantum BioPharma Ltd. Fraud Investigation with the Schall Law Firm
Via Business Wire
News headline image
KILL Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM
Via Business Wire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Refutes Unsubstantiated Claims in Law Firm Announcements
Via Investor Brand Network
News headline image
Three Biotech Companies Redefining Value Creation Through Dual Strategies
Via ACCESS Newswire
News headline image
Quantum BioPharma Ltd. Responds to Vague and Misleading Allegations by The Schall Law Firm and DJS Law Group
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Launches Whistleblower Reward Program Offering up to $7 Million for Stock Manipulation Evidence
Via Investor Brand Network
Topics Lawsuit Regulatory Compliance Whistleblower
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Redefines Life Sciences with Digitally Engineered, Multi-Vertical Growth Model
Via Investor Brand Network
News headline image
Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock
Reward to be Paid if Information Contributes Significant Evidence Leading to a Trial Victory or Settlement in Landmark USD $700 Million+ Lawsuit 
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View
Via ACCESS Newswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Sets Record Date for Litigation-Linked CVR Distribution
Via Investor Brand Network
News headline image
Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case
From Quantum BioPharma
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances IND Application for Lucid-MS with Final Toxicity Reports
Via Investor Brand Network
News headline image
Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Appoints Dr. Jack Antel as Clinical Advisor for MS Program
Via Investor Brand Network
News headline image
Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Reports Results of Annual General and Special Meeting
Via Investor Brand Network
News headline image
Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders
From Quantum BioPharma
Via GlobeNewswire
News headline image
Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives Health Canada Product License for Qlarity
Via Investor Brand Network
News headline image
Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance
From Quantum BioPharma
Via GlobeNewswire
BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Licensee Unbuzzd Wellness to Host Investor Webinar on Sept. 16
Via Investor Brand Network
News headline image
Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT
From Quantum BioPharma
Via GlobeNewswire
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Receives BUY Rating, $45 Price Target from Kingswood Capital Partners
Via Investor Brand Network
News headline image
Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target
This was unpaid research with no consideration given 
From Quantum BioPharma
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.